한글목차

듀피젠트(dupilumab)는 인터류킨-4(IL-4)와 인터류킨-13(IL-13) 수용체 복합체에 공통적으로 존재하는 IL-4Ra 서브유닛에 특이적으로 결합하여 인터류킨-4(IL-4)와 인터류킨-13(IL-13)의 신호전달을 억제하는 인간형 단클론항체입니다. 듀피루맙은 'i형' 수용체를 통해 IL-4의 신호전달을 억제하고, 'II형' 수용체를 통해 IL-4와 IL-13의 신호전달을 모두 억제합니다.

IL-4Ra를 발현하는 여러 세포 유형(예: 비만세포, 호산구, 대식세포, 대식세포, 림프구, 상피세포, 컵세포)과 염증 매개체(예: 히스타민, 에이코사노이드, 류코트리엔, 사이토카인, 케모카인 등)가 염증에 관여합니다. 듀피루맙으로 IL4Ra를 억제하면 염증성 사이토카인, 케모카인, 산화질소, IgE의 방출을 포함한 IL-4 및 IL-13 사이토카인에 의한 염증 반응이 억제됩니다.

듀피젠트는 아토피 피부염, 천식, 비강 용종증을 동반한 만성 비부비동염(CRSwNP), 호산구성 식도염, 결절성 소양증 등 다양한 적응증으로 승인됐습니다.

이 보고서는 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본 등 주요 7개국의 CSU용 듀피젠트에 대한 2019년부터 2032년까지 상세한 현황과 CSU용 듀피젠트에 대한 자세한 설명을 함께 게재하고 있습니다. 또한 작용기전, 용법 및 용량, 규제 마일스톤을 포함한 연구개발 및 기타 개발 활동에 대한 인사이트를 제공합니다. 또한 주요 7개국 CSU용 듀피젠트 시장 예측 분석, SWOT, 애널리스트의 견해, 시장 경쟁사 개요, CSU용 다른 신흥 치료제 개요 등 향후 시장 평가도 포함돼 있습니다.

목차

제1장 보고서 소개

제2장 만성 특발성 두드러기(CSU)의 듀피젠트 개요

• 제품 상세
• 임상 개발
• 기타 발달 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법)

제4장 경쟁 구도(후기 단계 새로운 치료법)

제5장 듀피젠트 시장 평가

• 만성 특발성 두드러기(CSU)의 듀피젠트 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

영문목차

"DUPIXENT Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about DUPIXENT for Chronic Spontaneous Urticaria (CSU) in the seven major markets. A detailed picture of the DUPIXENT for CSU in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DUPIXENT for CSU. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DUPIXENT market forecast analysis for CSU in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in CSU.

Drug Summary:

DUPIXENT (dupilumab) is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the 'Type I' receptor and both IL-4 and IL-13 signaling through the 'Type II receptor'.

Multiple cell types that express IL-4Ra (e.g., mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines, chemokines) are involved in inflammation. Blocking IL4Ra with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including releasing proinflammatory cytokines, chemokines, nitric oxide, and IgE.

DUPIXENT is approved for multiple indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis, and prurigo nodularis.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DUPIXENT description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria (CSU).
• Elaborated details on DUPIXENT regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DUPIXENT research and development activities in CSU across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around DUPIXENT.
• The report contains forecasted sales of DUPIXENT for CSU till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CSU.
• The report also features the SWOT analysis with analyst views for DUPIXENT in CSU.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DUPIXENT Analytical Perspective by DelveInsight

• In-depth DUPIXENT Market Assessment

This report provides a detailed market assessment of DUPIXENT for Chronic Spontaneous Urticaria (CSU) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• DUPIXENT Clinical Assessment

The report provides the clinical trials information of DUPIXENT for Chronic Spontaneous Urticaria (CSU) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Chronic Spontaneous Urticaria (CSU) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DUPIXENT dominance.
• Other emerging products for CSU are expected to give tough market competition to DUPIXENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DUPIXENT in CSU.
• Our in-depth analysis of the forecasted sales data of DUPIXENT from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DUPIXENT in CSU.

Key Questions:

• What is the product type, route of administration and mechanism of action of DUPIXENT?
• What is the clinical trial status of the study related to DUPIXENT in Chronic Spontaneous Urticaria (CSU) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DUPIXENT development?
• What are the key designations that have been granted to DUPIXENT for CSU?
• What is the forecasted market scenario of DUPIXENT for CSU?
• What are the forecasted sales of DUPIXENT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to DUPIXENT for CSU?
• Which are the late-stage emerging therapies under development for the treatment of CSU?

Table of Contents

1. Report Introduction

2. DUPIXENT Overview in Chronic Spontaneous Urticaria (CSU)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DUPIXENT Market Assessment

• 5.1. Market Outlook of DUPIXENT in Chronic Spontaneous Urticaria (CSU)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DUPIXENT in the 7MM for Chronic Spontaneous Urticaria (CSU)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DUPIXENT in the United States for Chronic Spontaneous Urticaria (CSU)
  • 5.3.2. Market Size of DUPIXENT in Germany for Chronic Spontaneous Urticaria (CSU)
  • 5.3.3. Market Size of DUPIXENT in France for Chronic Spontaneous Urticaria (CSU)
  • 5.3.4. Market Size of DUPIXENT in Italy for Chronic Spontaneous Urticaria (CSU)
  • 5.3.5. Market Size of DUPIXENT in Spain for Chronic Spontaneous Urticaria (CSU)
  • 5.3.6. Market Size of DUPIXENT in the United Kingdom for Chronic Spontaneous Urticaria (CSU)
  • 5.3.7. Market Size of DUPIXENT in Japan for Chronic Spontaneous Urticaria (CSU)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options